PepGen downgraded by BofA Securities with a new price target
$PEPG
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2025 | $6.00 | Buy | Guggenheim |
| 12/16/2024 | $3.00 | Neutral → Underperform | BofA Securities |
| 7/31/2024 | $12.00 | Buy → Neutral | BofA Securities |
| 12/21/2022 | $26.00 | Buy | H.C. Wainwright |
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
Guggenheim initiated coverage of PepGen with a rating of Buy and set a new price target of $6.00
BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00
BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference (Boston, MA) Monday, November 10, 2025 at 11:30 a.m. ET, Fireside Chat Stifel 2025 Healthcare Conference (New York, NY) Thursday, November 13, 2025 at 4:00 p.m. ET, Fireside Chat A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company's data will be presented in two oral presentations at the 30th Annual International Congress of the World Muscle Society (WMS) being held October 7-12, 2025, in Vienna, Austria. One of the presentations will include previously reported positive FREEDOM-DM1 Phase 1 clinical data. Title: Results from 15 mg/kg single dose PGN-EDODM1 cohort of FREEDOM-DM1- a phase 1 study in people with myotonic dystrophy type 1 (DM1) (#230) Session: Clinical T
PepGen Inc. (NASDAQ: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public offering of 35,937,500 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 4,687,500 additional shares, at the public offering price of $3.20 per share. The aggregate gross proceeds to PepGen from this offering, before deducting underwriting discounts and commissions and offering expenses, were $115 million. Leerink Partners and Stifel acted as
SCHEDULE 13G - PepGen Inc. (0001835597) (Subject)
8-K - PepGen Inc. (0001835597) (Filer)
SCHEDULE 13D/A - PepGen Inc. (0001835597) (Subject)
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
– Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived